Selvigaltin (GB1211), an orally available small molecule galectin-3 inhibitor developed being a therapy for liver fibrosis and cirrhosis, was evaluated to assess the outcome of hepatic impairment on its pharmacokinetics and safety to handle regulatory requirements. Desk four Statistical assessment of dose proportionality of your pharmacokinetic parameters of GB1211 adhering https://rudyd443sdo6.nizarblog.com/profile